What does this research mean for the field?

Platelet GP IIb-IIIa inhibitors function as effective therapeutic agents for acute ischemic syndromes and as adjuvants to prevent ischemic complications during percutaneous revascularization. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

Summarize findings from prospective, controlled clinical trials evaluating platelet glycoprotein IIb-IIIa inhibitors in managing acute coronary syndromes and percutaneous coronary revascularization.

January 1, 1997Current Opinion in Hematology

Inhibitors of the platelet GP IIb-IIIa function in the treatment of acute coronary syndromes

Q: What is the clinical evidence from this study?

Study design: Review. Population: Acute coronary syndromes and ischemic complications of percutaneous coronary revascularization. Intervention: Inhibitors of platelet GP IIb-IIIa.

View Full Paper

Ask AI

Bookmark

Key result

Review summarizes trial evidence for GP IIb-IIIa inhibitors in acute ischemic syndromes and percutaneous revascularization.

Why the study?

Do inhibitors of platelet GP IIb-IIIa improve outcomes in patients with acute coronary syndromes or undergoing percutaneous coronary revascularization?

Key Points

Summarize findings from prospective, controlled clinical trials evaluating platelet glycoprotein IIb-IIIa inhibitors in managing acute coronary syndromes and percutaneous coronary revascularization.
Reviewed evidence from prospective, controlled clinical trials evaluating glycoprotein IIb-IIIa inhibitors.
Assessed agents used as direct medical therapies for acute ischemic syndromes and as adjunctive treatments during percutaneous coronary revascularization procedures.
Glycoprotein IIb-IIIa inhibitors successfully target the final common pathway of platelet aggregation to counteract ischemic complications.
Controlled trial evaluations support the clinical utility of GP IIb-IIIa inhibition alongside standard thrombin and platelet therapies in acute ischemic settings.

Structured PICO

Do inhibitors of platelet GP IIb-IIIa improve outcomes in patients with acute coronary syndromes or undergoing percutaneous coronary revascularization?

Population

Patients with acute coronary syndromes or undergoing percutaneous coronary revascularization

Intervention

Inhibitors of platelet GP IIb-IIIa

This review summarizes the clinical evaluation of GP IIb-IIIa inhibitors as therapeutics for acute ischemic syndromes and adjuvants for percutaneous revascularization.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Synthesizes trial evidence on GP IIb-IIIa inhibitors in ACS and PCI; leaves open their role amid evolving antithrombotic strategies.

Cite This Study

Aaron D. Kugelmass (1997) conducted a review in Acute coronary syndromes and ischemic complications of percutaneous coronary revascularization. Inhibitors of platelet GP IIb-IIIa was evaluated. This review summarizes the results of prospective, controlled trials evaluating platelet GP IIb-IIIa inhibitors as therapeutics for acute ischemic syndromes and adjuvants for percutaneous revascularization.

synapsesocial.com/papers/6aa7577b0257261059f63e4a https://doi.org/10.1097/00062752-199704050-00001

Topics

Dual antiplatelet therapy

View Full Paper

Ask AI

Bookmark

Inhibitors of the platelet GP IIb-IIIa function in the treatment of acute coronary syndromes

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Topics

Inhibitors of the platelet GP IIb-IIIa function in the treatment of acute coronary syndromes

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Also Consider

Topics

Also Consider